Stephen K. Brannan - 09 Feb 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Medical Officer
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 09 Feb 2023
Net transactions value: -$934,600
Form type: 4
Filing time: 13 Feb 2023, 15:36:18 UTC
Previous filing: 09 Jan 2023
Next filing: 09 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$27,250	+5,000	+33%	$5.45^*	20,000	09 Feb 2023	Direct
transaction	KRTX	Common Stock	Sale	$961,850	-5,000	-25%	$192.37	15,000	09 Feb 2023	Direct	F1
transaction	KRTX	Common Stock	Award	$0	+8,650	+58%	$0.000000	23,650	09 Feb 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-5,000	-14%	$0.000000	29,677	09 Feb 2023	Common Stock	5,000	$5.45	Direct	F3
transaction	KRTX	Option (right to buy)	Award	$0	+17,350		$0.000000	17,350	09 Feb 2023	Common Stock	17,350	$187.26	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2	Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 9, 2024, subject to continued service through such dates.
F3	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F4	25% of this option shall vest on February 9, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.